Vancomycin Taper to Prevent Recurrent Clostridioides Difficile | MicrobiomeTrials← Back to trialsNCT07328971
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-24Est. Completion: 2030-06-01
Enrollment target: 500 participants Locations- McGill University Health Centre, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…
Izmir, Turkey (Türkiye)Est. completion May 30, 2027
DysbiosisClostridium DifficilePet-Human BondingAntibiotic-Associated Colitis
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a diseas…
Philadelphia, United StatesEst. completion Sep 1, 2026
Ulcerative ColitisInflammatory Bowel DiseasesClostridioides Difficile Infection
This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded…
Calgary, CanadaEst. completion Mar 1, 2028